anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated Dgr;8,9 dehydroestrone, conjugated 17agr; estradiol, conjugated 17agr; dihydroequilin, conjugated 17agr; dihydroequilin, conjugated 17bgr; estradiol, conjugated equilenin, conjugated 17agr; dihydroequilenin, and conjugated 17bgr; dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
A liquid composition comprises a salicylate compound, preferably selected from the group consisting of aspirin, diflusal, diflunisal, salsalate and salicylic acid; a glycerol derivative, preferably glycerin triacetate; and a saccharin compound, preferably saccharin. Preferably the composition comprises aspirin (acetylsalicyclic acid), glycerine triacetate (triacetin) and saccharin. The composition may further comprise a flavouring agent, in particular mint oil. Preferably the concentration of the salicylate compound is 0.5 to 3% and/or the concentration of the glycerol derivative is preferably 94 to 99%. The concentration of the saccharin compound is preferably 0.1 to 3%. The salicylate compound is soluble in the composition, which is particularly suitable for oral, parenteral or pulmonary administration. A method of preparing a liquid composition comprising admixing a salicylate compound, glycerol derivative, and a saccharin compound is also provided.
<P>PROBLEM TO BE SOLVED: To realize setting of a medication scheduling time without operating a time setting button in a medication management support apparatus with a medication notifying function.  <P>SOLUTION: If a user closes the cover of a medicine box at 6:18 a.m. before 6:32 a.m. of a medication completion time, a controller 11 stores 6:18 a.m. as the medication completion time in a medication completion time storage unit 14a, and a liquid crystal display unit 17 displays flashing. Then, the controller 11 adds or subtracts an adjustment time (e.g. positive 10 min) to or from 6:18 a.m. to calculate the medication scheduling time of the next day, and stores the medication scheduling time in a medication scheduling time storage unit 14b. Therefore, the medication scheduling time of the next day is automatically updated from 6:32 a.m. to 6:28 a.m. If the user does not open or close the cover of the medication box up to 6:30 a.m. of the medication scheduling time, the controller 11 drives a buzzer 18 to perform the medication notification.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Systems and methods for generating a 3D model of a dentition are disclosed herein. A method includes generating a first 3D model of a dentition including a plurality of model teeth. The method includes receiving at least one digital representation comprising patient teeth. The method includes determining a virtual camera parameter. The virtual camera parameter corresponds with a camera used to capture the digital representation. The method includes comparing, based on the virtual camera parameter, a first position of a model tooth with a position of a corresponding patient tooth of the digital representation. The method includes moving the model tooth from the first position to a second position. The second position is based on the position of the corresponding patient tooth. The method includes generating a second 3D model comprising the model tooth of the first 3D model in the second position.
Particles such as islet cells are encapsulated by a method that forms a coating of uniform thickness that conforms to the size and shape of the particles. Two substantially immiscible liquids of different densities are provided in a container as upper and lower liquids such that an interface exists between the liquids. The upper liquid is less dense and has a greater viscosity than the lower liquid which is a coating liquid containing particles to be encapsulated. A tube is positioned in the upper liquid such that an orifice of the tube is above the interface. A pump connected to the tube sucks liquid through the tube at a rate sufficient to form a spout containing substantially the lower liquid extending between the interface and the tube orifice. The spout has maximum diameter at the interface and decreases in diameter as the spout approaches the tube orifice. Particles in the lower liquid are drawn up through the spout as liquid is withdrawn, and coated particles are released from the spout at a point where the diameter of the spout is less than the diameter of the particles, and the coated particles flow through the tube. The coating liquid may be a pre-polymer that can be polymerized and crosslinked after coating. The coated particles have therapeutic applications such as administering coated islet cells to treat diabetes.
The present invention discloses suppository for detoxicating and promoting blood circulation and a preparing method thereof, which aims to provide the suppository for detoxicating and promoting blood circulation, which has the advantages of fast effect, short course of treatment, good curative effect, no relapse, no stimulation and small side effect. The inner contained materials of the suppository for detoxicating and promoting blood circulation are mainly made of raw materials of coptis, red peony root, borneol, natural indigo, red sage root and twotoothed achyranthes root. The present invention has the efficiency of clearing heat, drying damp, detoxifying, promoting blood circulation, dispelling stasis and alleviating pain. Because the present invention is used in a rectal mode, the phenomenon of damage by first pass function of the liver of oral administration medicine after medication is avoided, and the harm to the liver, the kidney, etc. is avoided. What is more important is that because an administration position approaches an illness position, the absorption is rapid after medication; thus, the curative effect is quickly exerted, and the course of treatment is greatly shortened. The present invention is suitable for treating humid heat stasis type chronic prostatitis.
The present invention relates to the composition of an oral bioadhesive endoparasiticide gel based on doramectin, having a high degree of adhesion to equine oral mucosa and having a sweet flavour greatly facilitating the dosing thereof, procedures for the preparation and the utilisation thereof. Gastrointestinal helminthosis is a parasitic condition caused by nematodes of diverse families occasioning serious gastrointestinal disorders in equine livestock. Control of this illness is of great importance and advantageously achievable through the employment of appropriate antihelminthic agents such as doramectin, being a chemical compound widely administered by parenteral route and infrequently by oral route in liquid form due to the organoleptic and physicochemical characteristics of the compositions known up to the present.; The present invention demonstrates that it is possible to administer doramectin in the pharmaceutical form of an oral gel at concentrations of up to 5.0% weight/volume, overcoming the organoleptic and physicochemical restrictions of the compositions known up to the present. Factors never heretofore included in oral endoparasiticide compositions based on doramectin, presenting a wide differential advantage compared with the compositions known up to the present. These and other characteristics, objectives and advantages of the present invention will be appreciated by those skilled in the art from the detailed description provided below in the present document, together with the attached claims.
A number of studies have confirmed that Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ)-transcriptional enhanced associate domain (TEAD) activity is the driver of cancer development. However, the role and mechanism of the YAP/TAZ-TEAD pathway in cervical intraepithelial neoplasia (CIN) remain to be clarified. Therefore, this study was designed to observe the effect of YAP/TAZ-TEAD activity on the development of CIN and provide new ideas for the diagnosis and treatment of CIN. Firstly, cervical tissues were collected from CIN patients in different stages [CIN grade 1 (CIN1) tissue, CIN grade 2/3 (CIN 2/3) and squamous cell carcinoma (SCC)] and healthy volunteers. Next, the expression levels of YAP, TAZ and TEAD in cervical tissues and cells were observed by immunohistochemistry, qRT-PCR and western blot. Besides, Z172 and Z183 cells were transfected with siRNA-YAP/TAZ (si-YAP/TAZ) and YAP/TAZ overexpression vector (YAP-5SA). Also, Z172 cells were co-transfected with YAP-5SA and si-TEAD2/4. Subsequently, the stemness characteristics, glycolysis level and malignant transformation of cells in each group were observed by sphere-formation assay, commercial kit, MTT, Transwell, scratch experiment, xenotransplantation and western blot.The expression of YAP, TAZ and TEAD increased significantly in cervical cancer tissue and cell line at the stage of CIN2/3 and SCC. When YAP/TAZ was knocked down, the stemness characteristics, glycolysis level and malignant transformation of cancer cells were notably inhibited; while activating YAP/TAZ exhibited a completely opposite result. In addition, activating YAP/TAZ and knocking down the TEAD expression at the same time significant weakened the effect of activated YAP/TAZ signal on precancerous cells and reduced inhibitory effect of knocking down TEAD alone. YAP/TAZ-TEAD signal activates the characteristics and Warburg effect of cancer stem cells, thereby promoting the malignant transformation of CIN.
PURPOSE:To provide a nasotracheal administration emulsion containing a parathyroid hormone as an active ingredient and having good absorbability and high stability. CONSTITUTION:The objective emulsion contains a parathyroid hormone (PTH) in an amount of 10-10000 units per ml of the emulsion as an active ingredient. An azacycloalkane derivative of the formula (R is alkyl; m is 2-4; n is 1-15; but when n is 1-3, R is 5-11C alkyl), glycyrrhetic acid or its non-toxic salt as a absorption-promoting agent and water are further added to the emulsion. The compound of the formula and glycyrrhetic acid are added in amounts of 0.01-10W/V% and 0.1-5W/V%, respectively, to the emulsion. The emulsion is sprayed into one or both of nares once to three times for 1-2 days with a constant volume sprayer (0.05-0.1ml/stroke). The PTHs, are e.g. h-PTH (1-34)), etc., which are peptide having a serum calcium-raising action, a mol.wt. of 4000-10000 and a sequence comprising 34-84 amino acids.
Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA \>.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
The test product, generic empagliflozin 25 mg film-coated tablets, will be formulated using the same active ingredient with the same strength as the reference product, JARDIANCE®. The test product to be used in this bioequivalence study is prepared in accordance with GMP regulations.
Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
Early Treatment: During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol as soon as possible after the patient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. 

Begin treatment in this early phase with the intravenous administration of three bolus injections of 5 mg of metoprolol each; give the injections at approximately 2-minute intervals. During the intravenous administration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram. 

In patients who tolerate the full intravenous dose (15 mg), initiate metoprolol tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose and continue for 48 hours. Thereafter, the maintenance dosage is 100 mg orally twice daily. 

Start patients who appear not to tolerate the full intravenous dose on metoprolol tablets either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose or as soon as their clinical condition allows. In patients with severe intolerance, discontinue metoprolol (see WARNINGS).
This study will investigate the effect of daily consumption of purple wheat bran-enriched wholegrain convenience bars, for 8 weeks on inflammation and oxidative stress biomarkers and plasma antioxidant capacity. This study is a randomized, parallel arm study with 20 men and 20 women who will adhere to a low anthocyanin and low phenolic aid diet for the duration of the study. The participants will be randomly divided into two groups, using stratification for matching sex and screening hs-CRP level to be equally distributed in each group, and assigned to either the treatment group or control group. Both group will have a 10 day diet run-in period where consumption of foods rich in anthocyanins and phenolic acids will be limited. Both groups will consume 4 servings of wheat products per day for 8 weeks and will replace 4 grain servings from their typical daily intake with the study treatment products. Fasting blood samples will be collected during three study visits, including baseline, for the analysis of inflammatory and oxidative stress biomarkers and plasma antioxidant capacity. The plasma metabolites of anthocyanins and phenolic acids will also be determined.
The invention discloses a traditional Chinese medicine preparation used for treating neurosurgery post-operation headache. It is considered by traditional Chinese medicine that brain is the gathering place of blood and essence, and headache may be caused by both internal injuries and external infection. The traditional Chinese medicine preparation is prepared by subjecting gardneria angustifolia, Viola philippica Cav. Subsp. Malesi-ca W. Beck., Oenanthe benghalensis, boraginaceae, erythrina arborescens roxb., honeysuckle stem, lycopodium fargesii Hert, Rheum franzenbachii Munt., Halorrhagis micrantha R. Brown, rheum officinale, and Utricularia bifida to water decoction so as to obtain a decoction. It is confirmed by clinical experiments that total effective rate is as high as 98%, and is obvious higher than that of a control group.
Disclosed is a formula of a watermelon-taste mouthwash. The watermelon-taste mouthwash comprises essence, a surfactant, sodium fluoride, ethyl alcohol, water and watermelon juice. Essence can keep the oral cavity fresh. The surfactant has functions including moistening, permeating, deterging and defoaming. Sodium fluoride can protect teeth and prevent tooth decay. Ethyl alcohol has a slight disinfection effect and can also improve the mouthfeel. Watermelon juice can enhance the sense of taste. The formula of the watermelon-taste mouthwash has the advantages that by using the mouthwash, teeth can be better protected, and taste is better.
Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is a well-established noninvasive procedure for the evaluation and risk stratification of patients with coronary artery disease (CAD) (1). However, it has been recognized that in certain patients SPECT MPI is unable to detect the presence of or underestimates the extent of CAD. The fact that moderate to severe perfusion defects are noted in less than half of the patients with significant left main disease (2) has stimulated studies to improve the diagnostic accuracy of SPECT MPI. Such studies have analyzed post-stress parameters such as left ventricular (LV) ejection fraction (EF) (3, 4), wall motion abnormalities (5) and transient LV dilation (6) with images acquired on conventional Anger cameras as long as 60 minutes after the stress tracer injection. Such delayed assessment may miss early ischemic stunning as a result of its transient nature. However, detection of an early post-stress decrease in cardiac output (CO) may serve as a potential marker for the presence of significant or extensive ischemia. The aim of this study is to test for an early post-stress CO change by impedance cardiography and its relation to the severity and extent of myocardial ischemia and angiographic coronary disease in subjects undergoing exercise stress testing using a novel cadmium-zinc-telluride (CZT) SPECT camera.
Hemorrhage is the leading cause of trauma death, and innovation in hemostatic technology is important. The strongly hydrophobic carbon nanofiber (CNF) coating has previously been shown to have excellent hemostatic properties. However, the understanding of how CNF coating guides the coagulation cascade and the biosafety of CNF as hemostatic agents has yet to be explored. Here, our thrombin generation assay investigation showed that CNF induced fast blood coagulation via factor (F) XII activation of the intrinsic pathway. We further performed studies of a rat vein injury and demonstrated that the CNF gauze enabled a substantial reduction of blood loss compared to both the plain gauze and kaolin-imbued gauze (QuikClot). Analysis of blood samples from the model revealed no acute toxicity from the CNF gauze, with no detectable CNF deposition in any organ, suggesting that the immobilization of CNF on our gauze prevented the infiltration of CNF into the bloodstream. Direct injection of CNF into the rat vein was also investigated and found not to elicit overt acute toxicity or affect animal survival or behavior. Finally, toxicity assays with primary keratinocytes revealed minimal toxicity responses to CNF. Our studies thus supported the safety and efficacy of the CNF hemostatic gauze, highlighting its potential as a promising approach in the field of hemostatic control.
The container comprises an edge-sealed bag (10) with a multi-layer, liquid-tight rear wall (11), welded along its four outer edges to a front wall (12) of the same material and of the same size. PREFERRED MATERIALS - The volume of the bag so formed corresp. to 0.5-3.0 adhesive, pref. accommodating about 2 g of adhesive. The walls of the bag are pref. made of a polyethylene terephthalate/ALU/polyethylene film, with the polyethylene coating on the inside of the walls. The adhesive is of highly compressed collidine with a vitamin C addition. <IMAGE>
Patients receive SNDX-5613 PO BID and gilteritinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration, and blood sample collection throughout the study.
OBJECTIVE: The Hospital Frailty Risk Score (HFRS) is a recently developed tool that uses ICD-10 codes to measure patient frailty. However, the effectiveness of HFRS has not yet been assessed in meningioma patients specifically. The present study aimed to evaluate the effectiveness of HFRS in predicting surgical outcomes for patients with meningiomas.
METHODS: This retrospective study utilized data from patients undergoing meningioma resection at a single institution (2017-2019). Data were obtained through a combination of automated data retrieval and manual chart review. Bivariate logistic regression was used to assess the prognostic ability of several frailty indices for predicting postoperative outcomes. Further, discrimination for each model was assessed using the area under the receiver operating characteristic curve (AUROC). Generalized linear models with gamma error distributions and a log-link function were used to model hospital length of stay (LOS), total charges, complications, and disposition.
RESULTS: A total of 464 meningioma patients (mean age 58.20 years, 72.8 % female, 66.4 % white) were included. HFRS had a significantly greater AUROC when compared to ASA (p = 0.0074) for postoperative complications, and HFRS significantly outperformed ASA (p = 0.0021) and mFI-5 (p = 0.018) when predicting nonroutine discharge. On multivariate analysis, increasing HFRS scores were significantly and independently associated with greater LOS (p < 0.0001), higher hospital charges (p < 0.0001), higher odds of postoperative complications (OR = 1.05, p = 0.019), and nonroutine discharge (OR = 1.12, p < 0.0001). The HFRS was non-inferior compared to the mFI-5, CCI, ASA and mFI-11 in terms of model discrimination.
CONCLUSION: HFRS effectively predicts postoperative outcomes for meningiomas and outperforms other indices in predicting complications and nonroutine discharge. This novel index may be used to improve clinical decision-making and reduce adverse postoperative outcomes among meningioma patients.
Acute kidney injury (AKI) is a common, multicause clinical condition that, if ignored, often progresses to chronic kidney disease (CKD) and end-stage kidney disease, with a mortality rate of 40-50%. However, there is a lack of universal treatment for AKI. Inflammation is the basic pathological change of early kidney injury, and inflammation can exacerbate AKI. Macrophages are the primary immune cells involved in the inflammatory microenvironment of kidney disease. Therefore, regulating the function of macrophages is a crucial breakthrough for the AKI intervention. Our team chemically modified pyxinol, an ocotillol-type ginsenoside, to prepare PJ16 with higher solubility and bioavailability. In vitro, using a model of macrophages stimulated by LPS, it was found that PJ16 could regulate macrophage function, including inhibiting the secretion of inflammatory factors, promoting phagocytosis, inhibiting M1 macrophages, and promoting M1 transition to the M2c macrophage. Further investigation revealed that PJ16 may shield renal tubular epithelial cells (HK-2) damaged by LPS in vitro. Based on this, PJ16 was validated in the animal model of unilateral ureteral obstruction, which showed that it improves renal function and inhibits renal tissue fibrosis by decreasing inflammatory responses, reducing macrophage inflammatory infiltration, and preferentially upregulating M2c macrophages. In conclusion, our study is the first to show that PJ16 resists AKI and fibrosis by mechanistically regulating macrophage function by modulating the phenotypic transition from M1 to M2 macrophages, mainly M2c macrophages.
Osteosarcoma is the most prevalent malignant bone tumour in children, adolescents and young adults. Despite a multitude of aberrations present in osteosarcoma genomes, no recurrent driver mutations have been identified to date. In addition, unlike for other sarcoma entities, no functional fusion proteins resulting from chromosomal rearrangements have been reported. Part of the genetic complexity of osteosarcoma might, however, be explained by the association of osteosarcoma with germline and somatic mutations of the major tumour suppressor TP53 that safeguards genomic integrity. By demonstrating that TP53 promoter translocations resulting in transcriptionally active fusion genes are a recurrent event in osteosarcoma, long-learnt paradigms are challenged by a recent publication by Saba, Difilippo et al. Osteosarcoma no longer appears to be a fusion-negative tumour, and by hardwiring cellular stress responses that transactivate the TP53 promoter to an oncogenic fusion partner, TP53 can be subverted and turned into an oncogene.